Stock-Based Compensation for Pfizer (PFE)
Stock-Based Compensation for Pfizer (PFE): headline value $574.00M · YoY -100.0%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
PFE
Currently viewingStock-Based CompensationSwitch metric
Latest period
$574.00M
YoY change
-100.0%
5Y CAGR
-100.0%
Peak year (2021)
$1.18B
Latest annual
$0
Stock-Based Compensation history chart for Pfizer (PFE) from 1989 to 2025
Stock-Based Compensation history table for Pfizer (PFE) from 1989 to 2025
| Fiscal year | Period ended | Reported | Stock-Based Compensation | YoY |
|---|---|---|---|---|
| 2025 | $0 | -100.0% | ||
| 2024 | $877.00M | +67.0% | ||
| 2023 | $525.00M | -39.8% | ||
| 2022 | $872.00M | -26.2% | ||
| 2021 | $1.18B | +56.3% | ||
| 2020 | $756.00M | +5.3% | ||
| 2019 | $718.00M | -24.3% | ||
| 2018 | $949.00M | +13.0% | ||
| 2017 | $840.00M | +21.6% | ||
| 2016 | $691.00M | +3.3% | ||
| 2015 | $669.00M | +14.2% | ||
| 2014 | $586.00M | +12.0% | ||
| 2013 | $523.00M | +8.7% | ||
| 2012 | $481.00M | +14.8% | ||
| 2011 | $419.00M | +3.5% | ||
| 2010 | $405.00M | +16.0% | ||
| 2009 | $349.00M | — | ||
| 2008 | $0 | — | ||
| 2007 | $0 | — | ||
| 2006 | $0 | — | ||
| 2005 | $0 | — | ||
| 2004 | $0 | — | ||
| 2003 | $0 | — | ||
| 2002 | $0 | — | ||
| 2001 | $0 | — | ||
| 2000 | $0 | — | ||
| 1999 | $0 | — | ||
| 1998 | $0 | — | ||
| 1997 | $0 | — | ||
| 1996 | $0 | — | ||
| 1995 | $0 | — | ||
| 1994 | $0 | — | ||
| 1993 | $0 | — | ||
| 1992 | $0 | — | ||
| 1991 | $0 | — | ||
| 1990 | $0 | — | ||
| 1989 | $0 | — |
Stock-Based Compensation values are taken from Pfizer's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
2025's annual stock-based compensation for Pfizer (PFE) came in at $0 – plunged 100.0% year-over-year.
Over 2020–2025 (5 years), Pfizer stock-based compensation expanded at a -100.0% compound annual rate, with a net decline across the window.
$1.18B stands as the all-time-high annual stock-based compensation, posted in 2021, against a low of $0 during 1989.
Pfizer (PFE) sits 5th of 8 Healthcare peers we track on this metric, against a peer median of $313.00M.
Pfizer Stock-Based Compensation by Year
Pfizer Stock-Based Compensation 2025: $0
Pfizer stock-based compensation in 2025 was $0, plunged 100.0% below 2024.
Pfizer Stock-Based Compensation 2024: $877.00M
Pfizer stock-based compensation in 2024 was $877.00M, surged 67.0% from 2023.
Pfizer Stock-Based Compensation 2023: $525.00M
Pfizer stock-based compensation in 2023 was $525.00M, plunged 39.8% below 2022.
Pfizer Stock-Based Compensation 2022: $872.00M
Pfizer stock-based compensation in 2022 was $872.00M, declined 26.2% below 2021.
Pfizer Stock-Based Compensation 2021: $1.18B
Pfizer stock-based compensation in 2021 was $1.18B.
See more financial history for Pfizer (PFE).
Sector peers — Stock-Based Compensation
Companies in the same sector as Pfizer, ranked by their latest stock-based compensation.
| Company | Stock-Based Compensation | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $1.35B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $971.00M | Healthcare |
| AbbVie Inc. (ABBV) | $955.00M | Healthcare |
| Eli Lilly and Company (LLY) | $626.00M | Healthcare |
| AstraZeneca PLC (AZN) | $0 | Healthcare |
| Merck & Co., Inc. (MRK) | $0 | Healthcare |
| Amgen Inc. (AMGN) | $0 | Healthcare |
| Novo Nordisk A/S (NVO) | $0 | Healthcare |
Frequently asked questions
What is Pfizer's stock-based compensation?
Latest reported stock-based compensation for Pfizer (PFE) is $574.00M (period ending December 31, 2025).
How has Pfizer stock-based compensation changed year-over-year?
Pfizer (PFE) stock-based compensation changed -100.0% year-over-year on the latest annual filing.
What is the long-term growth rate of Pfizer stock-based compensation?
Pfizer (PFE) stock-based compensation compound annual growth rate is -100.0% over the most recent 5 years available.
When did Pfizer stock-based compensation hit its highest annual value?
Pfizer stock-based compensation reached its highest annual value of $1.18B in 2021.
What was Pfizer stock-based compensation in 2024?
Pfizer (PFE) stock-based compensation in 2024 was $877.00M.
What was Pfizer stock-based compensation in 2025?
Pfizer (PFE) stock-based compensation in 2025 was $0.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
PFE Overview
Company profile, financial tools, and key metrics
PFE Revenue Counter
Earns $1,984 every second. See per minute, hour, and day.
PFE Earnings Counter
Earns $246.39 per second net profit. See per minute, hour, and day.
PFE Economic Scale
Exceeds Bolivia's GDP. Compare with world economies.
PFE What If Invested
What if you had invested $1,000? See historical returns from any date.
PFE How It Makes Money
Discover visual breakdown of $62.58B in revenue — where it comes from and where it goes.
PFE Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
PFE Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
PFE Daily Price Character
Steady · 46.3% historical win rate (green days). Streaks & record days.
PFE Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.
PFE Stock Split History
6 splits on record. Dates, ratios, and cumulative multiple.
PFE Dividend Profile
Yield: 6.55%. Safety: 3/8. See full history.
PFE Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
PFE Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.